Interventional Psychiatry Consortium

IPC Education Hub

Interactive clinical education on neuromodulation and interventional psychiatry, built from the IPC lecture series.

–
Live modalities
–
Review questions
–
Case simulations

A living resource that keeps evolving

Every new lecture is screened against every existing module before anything is added. Content is merged, sharpened, or replaced wherever newer material is stronger, and insights are carried into every section they touch, not only the one they came from. As new lectures and updates arrive, the summaries, clinical pearls, questions, and cases keep changing with the field.

Explore by topic

Summaries & clinical pearls

Structured overviews of each modality, with pearls on patient selection, parameters, safety, and evidence.

Review questions

Multiple-choice questions at foundational, intermediate, and advanced levels, with an explanation for every answer choice.

Case simulations

Step-by-step clinical decision points covering patient selection, treatment choices, and complications.

About this contentAI-supported educational content. This field advances quickly, so information may be outdated; please verify against current guidelines and primary sources before clinical use.
Overview
Accelerated TMS & SAINT
Modality · Noninvasive Brain Stimulation

Transcranial Magnetic Stimulation

Delivery of magnetic pulses over the scalp to stimulate the brain directly — modulating cortical excitability and depression-relevant circuits without surgery, anesthesia, or systemic side effects.

Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
Transcranial Magnetic Stimulation — Jarrod Ehrie, MD · Stanford University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
TMS uses a figure-8 coil containing a loop of conductive wire to generate a perpendicular magnetic pulse that crosses the scalp, skull, and meninges before converting back into an electrical field at the cortical surface. The left dorsolateral prefrontal cortex (DLPFC) is the primary FDA-cleared target for MDD — the most widely studied and clinically used. The dorsomedial PFC (DMPFC) is also FDA-cleared for MDD. Standard treatment is 36 sessions over 6 weeks, once daily Monday through Friday. Motor thresholding over the motor cortex establishes each patient's individual cortical excitability level, which is then used to dose treatment. Targeting is typically achieved via scalp heuristics (BeamF3 or adjusted BeamF3 method), though neuronavigation and fMRI-based targeting are increasingly used in specialized protocols. TMS also illustrates the experimental-medicine path to treatment development: frontal hypometabolism with left-greater-than-right asymmetry was framed as a response biomarker, frequency-specific protocols were built to undo it, and motor threshold individualizes dose as a biomarker of cortical excitability. In real-world open-label practice with the original 37-minute 10 Hz protocol, response rates were roughly 40–58% and remission rates 26–37%, and two head-to-head trials in patients who had failed at least two medications found TMS more effective than switching or augmenting medication — evidence that supports earlier use than most payers currently allow.
Core themes

Device, Mechanism & Setup

  • Figure-8 coil generates magnetic pulse → electrical field at cortex; coil shape, placement, and frequency vary by indication
  • Motor thresholding over motor cortex establishes cortical excitability — used to dose every patient individually; not one-size-fits-all
  • Left DLPFC is hypoactive in depression; subgenual anterior cingulate (sgACC) is hyperactive — these are the core circuit targets for TMS in MDD
  • TMS development followed an experimental-medicine path: frontal hypometabolism with left-greater-than-right asymmetry was framed as a response biomarker, and frequency-specific protocols (high frequency to raise the left, low frequency to lower the right) were built to undo it; prefrontal sites are now understood as entry points into a distributed network, and alpha-rhythm asymmetry is a further proposed response biomarker
  • TMS is a technology rather than a single treatment — different protocols are different treatments — and early data suggest individual alpha peak frequency may guide protocol choice: a peak near 10 Hz favors response to a 10 Hz protocol, while a peak closer to 8 or 12 Hz predicts weaker response and may favor another protocol

Protocols: Standard vs Theta Burst

  • Standard 10 Hz protocol: 37 minutes per session; theta burst (iTBS): 3 minutes 9 seconds — non-inferior efficacy with dramatically improved throughput (3× patients per hour); most TMS manufacturers now support iTBS
  • iTBS: 50 Hz triplets at 5 Hz intervals — mimics cortical theta rhythms; cTBS is suppressive (≈1 Hz); excitatory/inhibitory binary is likely an oversimplification at the DLPFC
  • Key stimulation parameters: pulse frequency, pulse shape (monophasic vs biphasic), charge per pulse, inter-train interval, and motor threshold % — all interact; SAINT uses 90% rMT with depth correction, conventional iTBS typically uses 120% rMT
  • D-cycloserine (NMDA partial agonist) augmentation of iTBS: 74% vs 29% response in RCT — NMDA receptor dependence of TBS plasticity is the mechanistic rationale; requires replication
  • "More is more" signal: non-responders to a 4-week course who continued twice-weekly TMS showed ongoing response accumulation through week 8 — no clear ceiling observed, supporting the scientific rationale for accelerated approaches

Indications, Evidence, Safety & Targeting

  • FDA-cleared: MDD, anxiety comorbid with MDD, refractory OCD, smoking cessation, migraine with aura — coil type and placement differ across indications
  • Standard course: 36 sessions, most insurances cover; seizure risk and hearing loss without ear protection are primary safety risks; headache and scalp discomfort most common side effects
  • Targeting methods: 5 cm rule → BeamF3 → adjusted BeamF3 → fMRI-based (used in SAINT); tape measure methods are cheap/accessible but anatomically imprecise
  • Real-world effectiveness: in an open-label study of 339 complex patients (comorbid anxiety, hypertension, diabetes, concurrent medications) treated with the original 37-minute 10 Hz protocol, response was roughly 40–58% and remission 26–37% depending on the outcome measure; the figures remain valid for 10 Hz, 1 Hz, and once-daily iTBS
  • Head-to-head evidence: two trials in patients who had failed at least two medications (one US-based, one in the Netherlands) found TMS more effective than switching or augmenting medication or the guideline-based next step; the FDA label requires failure of one or more medications, yet most payers still require four or more — with some beginning to lower the threshold to two
Source lectures
Transcranial Magnetic Stimulation — Jarrod Ehrie, MD · Stanford University
Special Populations — Sherab Tsheringla, MD · Yale University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
Physical Principles of Neuromodulation/Brain Stimulation for Clinicians — Marom Bikson, PhD · City College of New York (CUNY)

Clinical Pearls — TMS Overview

Source lectures
Transcranial Magnetic Stimulation — Jarrod Ehrie, MD · Stanford University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Review Questions — TMS Overview

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Transcranial Magnetic Stimulation — Jarrod Ehrie, MD · Stanford University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Case Simulation — TMS Overview

Stepwise clinical vignettes. Explore all options freely before continuing.

TMS Subtopic · Accelerated Protocols

Accelerated TMS & SAINT

Protocols delivering multiple TMS sessions per day over a compressed timeframe — dramatically shortening treatment duration while potentially exceeding the efficacy of conventional 6-week courses.

Source lectures
Transcranial Magnetic Stimulation — Jarrod Ehrie, MD · Stanford University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
Accelerated TMS broadly refers to protocols with multiple TMS sessions per day over at least 4 days per week for at least one week — though definitions vary significantly across trials. The rationale is that more magnetic pulses may produce greater antidepressant benefit, supported by data showing continued response accumulation with extended TMS courses. SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) is the most rigorously studied accelerated protocol and the only FDA-cleared accelerated TMS with insurance coverage. It delivers 10 sessions per day over 5 days (50 sessions total), each session containing 1,800 iTBS pulses at ~50-minute intervals, guided by resting-state fMRI targeting the DLPFC subregion with maximum negative connectivity to the sgACC. This delivers 5× the total pulses of a conventional iTBS course in one-sixth the calendar time.
Core themes

SAINT Protocol & fMRI Targeting

  • 10 sessions/day × 5 days; 1,800 pulses/session (3× conventional iTBS); ~50-min inter-session interval; delivers 90,000 total pulses vs 18,000 in conventional 30-session course
  • Resting-state fMRI identifies the DLPFC subregion with maximum negative connectivity to sgACC — anti-correlated targeting; overcomes the anatomical imprecision of tape-measure methods
  • 90% resting motor threshold with depth correction (adjusting for scalp-to-cortex distance at DLPFC vs motor cortex) — often results in higher effective stimulation than the 90% figure suggests

Clinical Evidence

  • Open-label: 90.5% remission at 4 weeks (86.4% ITT); double-blind RCT (n=29): 78.6% remission active vs 13.3% sham — striking separation from placebo unlike many antidepressant trials
  • Durability at 12 weeks: 47% remained in remission, 43% remained responders — comparable to acute remission rates of conventional protocols in similar populations
  • Retreatment: 74% remitted after both first and second SAINT courses; index and retreatment courses showed similar efficacy — supports repeat use when patients relapse

Maintenance, Safety & Unanswered Questions

  • Continuation paradigm: algorithm-guided additional SAINT days (avg 15 over 12 months); 85% of monitoring period in remission — potential path to sustained wellness without indefinite daily treatment
  • Safety: no seizures reported in research or clinical SAINT use; most common side effects fatigue, headache, scalp pain — similar profile to conventional TMS; no negative cognitive effects on neuropsych testing
  • The targeting question has now been answered in part: a head-to-head trial holding the accelerated schedule constant while randomizing connectivity-based vs scalp-based targeting found 83% vs 62% median MADRS improvement (roughly 80% vs 60% response), establishing that targeting contributes independently of pulse volume and session count
  • Sessions vs pulses: twice-daily iTBS (600 pulses × 2) vs once-daily 1200 pulses showed no clinical difference — same-day pulse doubling may not add benefit beyond a single higher-dose session; suggests it may be total pulses rather than session count that matters, though parameters are fundamentally interrelated
  • Accelerated without neuronavigation: open-label pilot (n=21) using 36 sessions over 5 days with BeamF3 targeting (standard 600 pulses/session, 60-min intervals) achieved 70% response and 55% remission at 4 weeks — simpler to implement than full SAINT but potentially stronger than conventional 6-week course
Source lectures
Transcranial Magnetic Stimulation — Jarrod Ehrie, MD · Stanford University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Clinical Pearls — Accelerated TMS & SAINT

Source lectures
Transcranial Magnetic Stimulation — Jarrod Ehrie, MD · Stanford University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Review Questions — Accelerated TMS & SAINT

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Transcranial Magnetic Stimulation — Jarrod Ehrie, MD · Stanford University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Case Simulation — Accelerated TMS & SAINT

Stepwise clinical vignettes. Explore all options freely before continuing.

TMS Subtopic · Circuit Targeting & Neuroimaging

Circuit Targeting & Neuroimaging

Using lesion network mapping and functional connectivity to identify where to stimulate — moving target selection from scalp measurement to circuit identification, across symptoms, disorders, and stimulation modalities.

Source lectures
Neurocircuitry of Mood Disorders: Circuit-Targeted Neuromodulation Across Symptoms and Disorders — Shan Siddiqi, MD · Northwestern University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
Circuit targeting reframes stimulation site selection as a network problem rather than a scalp measurement problem. Conventional TMS targets derive from the locations of brain lesions that cause depression, mapped in the 1980s and 1990s, which explains both why those landmarks work adequately for depression and why exporting them to PTSD, generalized anxiety, and addiction has produced inconsistent results. The modern framework is lesion network mapping: anatomically scattered lesions that produce the same symptom often connect to one common brain network, generating the therapeutic hypothesis that a network whose disruption causes a symptom is a candidate network to stimulate to relieve it. Applying this across 14 datasets and 713 patients drawn from three independent causal sources — brain lesions, TMS sites, and DBS sites — yielded a convergent depression circuit with the expected directionality, since 10 Hz TMS to the circuit relieved depression while lesions to the same circuit caused it, and subsequent work showed ECT-induced volume change in that circuit tracks clinical improvement. Because each data source carries different confounders, convergence supports causal rather than correlational inference. The same circuit sits beneath the 5 cm rule, the 6 cm rule, and BeamF3, which plausibly explains why successive scalp refinements produced only modest gains, and individualizing the target to a patient own connectivity peak improves outcomes across at least six retrospective cohorts and in a randomized head-to-head trial where connectivity-based targeting produced roughly 80% response versus 60% with scalp targeting. Symptom-level clustering further separated a depression circuit from a near anti-correlated anxiety circuit, subsequently validated against dedicated anxiety scales, with direct clinical consequences for treatment-emergent anxiety, coil selection, and DBS contact choice, while lesion-derived targets for psychosis, addiction, tics, tremor, epilepsy, and pain point toward a broader library of circuit-based treatment targets.
Core themes

Lesion Network Mapping & Causal Inference

  • Lesions causing the same symptom frequently do not overlap anatomically, but mapping each lesion onto a normative connectome shows they often connect to one shared network
  • Core hypothesis: if disrupting a circuit causes a symptom, stimulating that circuit may relieve it — the framework behind most current circuit-derived stimulation targets; because a stimulation site is an entry point into the network, well-connected hub nodes offer the best chance of circuit-wide effect
  • Convergence across lesions, TMS, and DBS is what licenses causal inference — each source has different confounders, so agreement across all three excludes explanations unique to any one
  • Normative connectome estimation is a real limitation but an acceptable approximation, because between-subject variance in lesion location far exceeds variance in network architecture
  • The method has now re-derived established targets for parkinsonism, tics, seizures, vertigo, tremor, and addiction, and is generating novel candidates where no target previously existed

The Depression Circuit & Personalized Targeting

  • Antidepressant efficacy of a stimulation site tracks its anti-correlation with the subgenual anterior cingulate — established in 2012, replicated prospectively, and the basis for fMRI-guided protocols
  • The convergent depression circuit already underlies the 5 cm rule, 6 cm rule, and BeamF3, plausibly explaining why decades of scalp-target refinement produced only modest gains
  • Individualized connectivity peaks outperform scalp landmarks across at least six retrospective cohorts (meta-analytic weighted r ≈ −0.28, n = 391); weaker effects track lower-resolution imaging, and no study has found the reverse
  • Randomized head-to-head trial: 83% vs 62% median MADRS improvement (≈80% vs 60% response) for connectivity-based vs scalp-based targeting, with a number needed to scan of about 5
  • A real-world clinic cohort reproduced the same ~20-point response gap after implementing fMRI guidance, with guidance the only variable predicting outcome after adjustment

The Anxiety Circuit & Symptom-Specific Target Selection

  • Data-driven clustering of symptom-level outcomes separated two circuits — initially dysphoric and anxiosomatic, later validated against dedicated anxiety scales as depression and anxiety circuits
  • The two circuits are close to anti-correlated, predicting that harder engagement of the depression circuit can worsen anxiety — consistent with a 20% treatment-emergent anxiety rate in the largest TMS trial
  • In patients with both depression and anxiety, a randomized active-controlled trial found the anxiety target superior for anxiety (58% vs 36% median BAI improvement) and equivalent for depression
  • Two incidental trials independently support the pattern, including a negative DMPFC trial whose comorbid-anxiety subgroup separated from sham while the non-anxious subgroup did not
  • Cross-modality implications: H1 and H7 deep TMS coils preferentially engage different circuits, and subthalamic DBS contacts differ in anxiety effect while remaining equivalent for motor symptoms
Source lectures
Neurocircuitry of Mood Disorders: Circuit-Targeted Neuromodulation Across Symptoms and Disorders — Shan Siddiqi, MD · Northwestern University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Clinical Pearls — Circuit Targeting & Neuroimaging

Source lectures
Neurocircuitry of Mood Disorders: Circuit-Targeted Neuromodulation Across Symptoms and Disorders — Shan Siddiqi, MD · Northwestern University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Review Questions — Circuit Targeting & Neuroimaging

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Neurocircuitry of Mood Disorders: Circuit-Targeted Neuromodulation Across Symptoms and Disorders — Shan Siddiqi, MD · Northwestern University
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Case Simulation — Circuit Targeting & Neuroimaging

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Modality · Psychedelic-Assisted Therapy

Psychedelics & Psychedelic-Assisted Psychotherapy

Serotonin 2A receptor agonists and related compounds that, combined with structured psychotherapeutic support, may produce rapid and durable therapeutic effects in depression, PTSD, and other treatment-resistant conditions — with a complex evidence base, significant methodological challenges, and a rapidly evolving regulatory landscape.

Source lectures
Psychedelics and Psychedelic-Assisted Psychotherapy — Natalie Gukasyan, MD · Columbia University / NYSPI
Classic psychedelics act primarily through 5-HT2A receptor agonism and include psilocybin, LSD, mescaline, and DMT. Downstream effects include glutamatergic modulation, mTOR and BDNF pathway activation promoting neuroplasticity, anti-inflammatory effects, reopening of critical periods, and shifts in brain network dynamics — particularly modulation of the default mode network. Non-classic psychedelics such as MDMA, ibogaine, ketamine, and salvia produce similar subjective experiences via distinct mechanisms. Research has occurred in two waves: a first wave (1950s–1970s) of largely poor-quality data, and a second wave beginning in the early 2000s that is more rigorous but still methodologically limited. Psychedelic-assisted therapy typically involves a preparation phase, one or more dosing sessions (each 6–8 hours) with two facilitators present, and subsequent integration sessions. The therapy component is substantial and almost certainly contributes independently to outcomes — the degree of that contribution is unknown and clinically important. FDA approval of psilocybin for MDD may arrive within 1–3 years. MDMA for PTSD was rejected by the FDA in 2024 due to concerns about functional unblinding, failure to assess drug-liking effects, conduct concerns in trials, and durability of benefit.
Core themes

Mechanisms & Compounds

  • Classic psychedelics: 5-HT2A agonism → downstream glutamate release, mTOR/BDNF activation, neurogenesis/synaptogenesis — mechanism parallels with ketamine but via different receptor entry point
  • Additional proposed mechanisms: anti-inflammatory effects, reopening of developmental critical periods, increased cognitive flexibility and emotional processing flexibility, default mode network disruption
  • Non-classic psychedelics: MDMA (amphetamine derivative, primarily monoaminergic), ibogaine (potent plant alkaloid, requires intensive cardiac monitoring — acute effects last ~30 hours), salvia — similar subjective experiences, different receptor profiles
  • Psychedelics as "non-specific amplifiers" (Tim Leary): they amplify both the contents of consciousness and the methodological problems inherent to psychiatric research

Clinical Evidence & Methodological Challenges

  • Hopkins psilocybin for MDD (n=24, waiting-list control): large effect sizes at 1–4 weeks post-treatment, maintained through 12 months; ~5-year follow-up survey shows sustained low depression scores — remarkable durability in a small study
  • Largest TRD psilocybin trial to date: 25 mg > 10 mg > 1 mg (placebo-equivalent) at 3 weeks for COMP360; statistical significance lost at 6 weeks in pre-specified model; 3 suicidal behaviors in high-dose group, all in non-responders with prior self-harm history
  • MDMA for PTSD (MAPS/Lykos): FDA rejected 2024 — failures to collect drug-liking data, ~40% prior MDMA exposure creating expectancy bias, concerns about therapist conduct in sessions, and durability of benefit beyond 18 weeks
  • Functional unblinding is near-universal: 90%+ of participants and staff can identify treatment arm; nosebo effects in those who believe they received placebo can inflate active-arm effect sizes
  • Therapy confounding: psychedelic trials involve many hours of preparation, dosing-day support, and integration — therapeutic alliance, expectancy, and non-pharmacologic factors almost certainly contribute; how much is unknown; no RCT design can fully disentangle them
  • Sample representativeness: 2018 review found 82% of psychedelic trial participants were non-Hispanic white, higher SES — evidence base may not generalize; racial disparity in naturalistic benefit data noted in survey studies

Implementation, Ethics & Regulatory Landscape

  • Cost: MAPS/Lykos MDMA therapy estimated at $11,000–12,000/patient, mostly therapist time (drug is inexpensive); break-even for insurers approximately 4 years — difficult coverage argument; initial access likely limited to those who can self-pay
  • Delivery model: two-therapist model is resource-intensive and limits access but has the strongest safety track record; alternatives under investigation include single therapist, group therapy, and AI/technology-assisted monitoring
  • Training gap: less than 50% of residency programs provide didactics on psychedelics; no consensus on required competencies; tri-institutional initiative (Hopkins, Yale, NYU) developing modular curriculum and fellowship framework
  • Ethical concerns: heightened suggestibility during sessions increases risk of boundary violations and internalization of therapist expectations; MAPS trials documented a case of serious misconduct involving an unlicensed therapist; use of supportive touch is common and creates a "slippery slope" requiring careful institutional policy
  • Legal/regulatory landscape: rapidly evolving; Oregon (psilocybin, 2023) and Colorado have legalized "supported adult use"; ~15,000 served in Oregon since launch; New York legislation pending; international: Australia approved limited therapeutic use; many countries allow ritual use
  • Access pathways outside clinical trials: state/local legalization, religious use exemptions (federally sanctioned for a small number of entities), international retreat centers, and underground providers (estimated thousands in the US)
  • Psychiatrist's role: lead teams rather than sit for 8-hour sessions; expertise in psychopharmacology (drug interactions, patient selection, serious adverse events); recognize and distinguish afterglow from hypomania/mania; coordinate master's-level therapists, nurses, and mid-level providers who will likely staff dosing sessions
Source lectures
Psychedelics and Psychedelic-Assisted Psychotherapy — Natalie Gukasyan, MD · Columbia University / NYSPI

Clinical Pearls — Psychedelics Overview

Source lectures
Psychedelics and Psychedelic-Assisted Psychotherapy — Natalie Gukasyan, MD · Columbia University / NYSPI

Review Questions — Psychedelics Overview

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Psychedelics and Psychedelic-Assisted Psychotherapy — Natalie Gukasyan, MD · Columbia University / NYSPI

Case Simulation — Psychedelics Overview

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Cross-modality · Special Populations

Pediatric, Adolescent & Neurodivergent Populations

Interventional psychiatry in children, adolescents, and neurodivergent individuals requires a distinct clinical framework — not a scaled-down adult approach. The four pillars of practice: rigorous developmentally-informed Assessment, equitable Access, thoughtful Augmentation of existing care, and unwavering Advocacy for the patient.

Source lectures
Special Populations — Sherab Tsheringla, MD · Yale University
The pediatric and neurodivergent population represents a critical and underserved frontier for interventional psychiatry. Depression prevalence in adolescents (ages 12–19) reaches up to 19% by CDC estimates, yet only two antidepressants are FDA approved for this age group, and treatment resistance definitions remain contested. Defining treatment resistance in children differs from adults: one adequate antidepressant trial plus failure of evidence-based psychotherapy may constitute treatment-resistant depression in adolescents (TRD-A), with two adequate trials constituting treatment-refractory depression. In autism spectrum disorder (ASD), standard treatments are less effective and carry greater side effect burdens partly due to neurobiological differences — including elevated whole blood serotonin and reduced serotonin receptor density in postmortem brain studies — which may explain why SSRIs frequently underperform. Neuromodulation approaches in these populations require developmentally informed adaptations, attention to maturation-stage considerations, and careful calibration of targets and expectations. The framework Dr. Tsheringla proposes — the Four A's: Assess, Access, Augment, Advocate — provides a practical clinical and ethical scaffold for interventionists entering this space.
Core themes

Treatment Resistance & Assessment in Youth

  • TRD in adolescents: failure of one adequate antidepressant trial + evidence-based psychotherapy may warrant IPS referral; two failed trials = treatment-refractory — thresholds are lower than adult standards given only two FDA-approved medications
  • ASD "treatment resistance" reflects neurobiological differences (elevated blood serotonin, reduced CNS serotonin receptors) — not simply medication non-compliance; polypharmacy burden is high and IPS may reduce it
  • Rating instruments must be adapted: DAS-21 shows better validity for neurodivergent individuals; Pediatric Catatonia Rating Scale preferred over Bush-Francis in youth; catatonia in autism presents as regression and self-injury, not just staring and rigidity
  • Evaluations must be holistic — psychological testing, play-based assessment, school/family collateral, and observational data are all clinically valid inputs, not administrative add-ons

Modality-Specific Considerations: ECT, TMS & Ketamine

  • ECT: indications mirror adults (catatonia, TRD, psychotic depression, NMS) — intellectual disability and SIB alone are NOT indications; children have lower seizure thresholds, higher rates of prolonged and TARDIVE seizures; state probate laws vary (CA: 12, TN: 14, TX: 16)
  • TMS: FDA cleared (2024) for MDD in adolescents ages 15–21; developmentally informed adaptations are essential (first-then boards, preferred videos, desensitization, behavioral rewards); no single optimal target in ASD — multiple networks are implicated
  • Ketamine/esketamine: neither is FDA approved for depression in youth; Spravato explicitly excludes ASD; emerging case reports and early trial data show rapid antidepressant effects — use remains off-label with heightened safeguards required
  • Catatonia prevalence in autism is up to 17% — screen proactively; ECT for catatonia in neurodivergent patients is evidence-based when benzodiazepines fail

The Four A’s: Assess, Access, Augment, Advocate

  • Assess: developmentally grounded, multi-source evaluations — standard adult instruments may be insufficient; play-based and observational data are valid; family and school are irreplaceable collateral sources
  • Access: workforce shortages, insurance gaps, and geographic barriers are real — not enough child psychiatrists nationally; authorization pathways for pediatric TMS and esketamine remain underdeveloped
  • Augment: IPS in children rarely replaces existing care — it augments and can reduce polypharmacy; comorbidity is the rule; multimodal coordination across school, family, therapist, and pediatrician is essential
  • Advocate: the interventionist’s role extends beyond the treatment room — probate navigation, insurance appeals, mental health parity enforcement, and systemic equity are all within scope
Source lectures
Special Populations — Sherab Tsheringla, MD · Yale University

Clinical Pearls — Special Populations Overview

Source lectures
Special Populations — Sherab Tsheringla, MD · Yale University

Review Questions — Special Populations Overview

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Special Populations — Sherab Tsheringla, MD · Yale University

Case Simulation — Special Populations Overview

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Modality · Surgical Neuromodulation

Vagus Nerve Stimulation

An implanted neurostimulator delivering intermittent electrical pulses to the left cervical vagus nerve, relaying signals through the nucleus tractus solitarius to monoamine-producing brainstem centers and limbic cortex — a bottom-up approach to treatment-resistant depression and epilepsy.

Source lectures
Surgical Treatments — Stephen Ferber, MD · Cleveland Clinic Foundation
VNS was FDA approved in 1997 for refractory epilepsy, and in 2005 for adjunctive long-term treatment of chronic or recurrent major depression in adults (18+) with an active MDE who have failed at least four adequate antidepressant treatments. The procedure involves subcutaneous implantation of a pulse generator (IPG) in the chest wall under general anesthesia, with electrode coils wrapped around the left cervical vagus nerve. The left side is preferred because the right vagus nerve innervates the sinoatrial node — right-sided stimulation risks bradycardia. Stimulation parameters (output current in mA, pulse width in µsec, frequency in Hz, and duty cycle) are adjusted via a programming wand and tablet. Titration begins two weeks post-implant at 0.25–0.5 mA and increases incrementally to a target of at least 1.0 mA — the estimated minimum therapeutic dose. Despite FDA approval, CMS declined coverage in 2007 citing the absence of sham-separation in the acute controlled phase of the initial approval trials; coverage was reopened for a large registry in 2018. VNS is notable for its delayed onset of benefit — response can take 12–24 months or longer, which confounds sham-controlled trial design and makes it difficult to counsel patients on expected timelines.
Core themes

Mechanism & Anatomy

  • ~80% of vagus nerve fibers are afferent (periphery → brain); afferent fibers have lower stimulation thresholds — left-sided stimulation primarily avoids visceral efferent effects, minimizing side effects
  • Primary relay: nucleus tractus solitarius (NTS) → locus coeruleus (NE), dorsal raphe (5-HT), parabrachial nucleus (CRF) → hippocampus, amygdala, thalamus, anterior insula, ventrolateral PFC, infralimbic cortex
  • Circuit effects overlap with DBS targets: VNS modulates the same limbic-prefrontal networks implicated in depression — connecting bottom-up brainstem drive to top-down cortical dysregulation

Parameters, Titration & Safety

  • Four independently adjustable parameters: output current (mA), pulse width (µsec), frequency (Hz), duty cycle (ON/OFF time ratio); typical maintenance: 20 Hz, 250 µsec, 30 sec ON / 5 min OFF (10% duty cycle)
  • Titration is imprecise — individual differences in nerve anatomy, electrode positioning, and tissue conductivity mean identical parameters produce different effective stimulation across patients; clinicians titrate against side effects
  • Most common adverse effect: hoarseness/voice change (27–68%), caused by stimulation of the left recurrent laryngeal nerve; occurs in real time during ON cycles and typically improves over 12–24 months; absolute contraindications: prior bilateral or left vagotomy, diathermy near the device

Evidence & Access Challenges

  • Landmark RCTs: Rush et al. 2005 (27% response/16% remission at 12 mo); Conway et al. 2025 — RECOVER trial (19% vs 16% active vs sham at 12 mo — no primary endpoint separation); Aaronson et al. 2013 (35–48% response / 20–23% remission in parallel design)
  • Critical limitation: VNS takes months to years to exert antidepressant effects — 10-week sham-controlled periods miss the window where separation would emerge; raising ethical concerns about extending sham periods in severely ill populations
  • Battery life 4–8 years depending on settings; rechargeable models now available; MRI compatibility is device- and field-strength-dependent — always consult manufacturer before imaging; VNS does not preclude TMS in most cases (ferromagnetism of device determines safety, not the mere presence of the device)
Source lectures
Surgical Treatments — Stephen Ferber, MD · Cleveland Clinic Foundation

Clinical Pearls — VNS Overview

Source lectures
Surgical Treatments — Stephen Ferber, MD · Cleveland Clinic Foundation

Review Questions — VNS Overview

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Surgical Treatments — Stephen Ferber, MD · Cleveland Clinic Foundation

Case Simulation — VNS Overview

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Modality · Surgical Neuromodulation

Deep Brain Stimulation

Continuous high-frequency electrical stimulation delivered via surgically implanted leads targeting discrete subcortical and white matter nodes — modulating dysfunctional neural networks in treatment-resistant depression and OCD through volumetric activation of connected circuits rather than focal ablation.

Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
Surgical Treatments — Stephen Ferber, MD · Cleveland Clinic Foundation
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai
DBS for psychiatric indications emerged serendipitously. OCD DBS (ALIC target) derived from prior anterior capsulotomy research (Nuttin et al., 1999, first case series of 4 patients). MDD DBS at the VC/VS target followed after patients with comorbid OCD and depression showed mood improvement post-implant (Greenberg et al., 2006). The procedure involves burr-hole implantation of quadrupolar leads (platinum-iridium contacts, polymer insulation) connected via subcutaneous extension wires to a titanium implanted pulse generator (IPG) in the infraclavicular pocket — now typically rechargeable (1–2×/week). The primary manufacturer in the US is Medtronic. Key programmable parameters are amplitude (V or mA — determines volume of tissue activated), pulse width (µsec — determines which neuronal elements are activated), and rate (Hz — nearly always 100–130 Hz based on temporal summation principles). DBS for depression remains investigational for most targets, with open-label studies showing 40–60% response and 25–35% remission — but pivotal RCTs have generally failed to demonstrate superiority over sham in the blinded phase, though longer open-label follow-up data are more compelling. Circuit-specific approaches now use patient-specific tractography to place the lead at the white matter intersection shared by responders, which has raised response rates in both depression and OCD and shifted programming toward a single fixed contact.
Core themes

Circuit Targets & Network Rationale

  • Four depression-relevant dysfunctional networks: affective (hyperconnected: sgACC–amygdala–insula–OFC → depressed mood); default mode (hyperconnected: mPFC–PCC–IPC–precuneus → rumination); reward (hypoconnected: NAcc–PFC → anhedonia); cognitive control (hypoconnected: dACC–dlPFC → executive dysfunction)
  • Major MDD DBS targets: SCC/BA25 (most studied), VC/VS (NAcc/ALIC), ITP/BNST, LHb, slMFB — each sits at a white matter confluence connecting multiple depression-relevant networks; stimulation VTA of ~3 mm can propagate through normative connectome to modulate distal cortical regions
  • Target selection is currently not biomarker-driven — adapted from movement disorder protocols or designed to evoke intraoperative emotional response; this imprecision is a major limitation and active research frontier

Parameters, Titration & Stimulation Modes

  • High frequency (100–130 Hz) is standard — justified by temporal summation: repeated sub-threshold EPSPs progressively depolarize the postsynaptic membrane until threshold is crossed; low-frequency stimulation has not produced benefit in psychiatric targets (its use is limited to select Parkinson disease gait and cognitive symptoms)
  • Two stimulation modes: monopolar (IPG = anode, lead contact = cathode → spherical field, larger VTA, lower threshold but more adjacent structure activation) vs bipolar (contacts serve as anode/cathode → ellipsoid field, smaller VTA, more focal, higher threshold)
  • Titration: check impedance first (high impedance = broken lead, fibrosis, or infection — infection can be delayed months post-implant); then systematically test each contact across amplitude range, mapping therapeutic window (benefit threshold vs adverse effect threshold) per contact; optimal contact is the one with the widest therapeutic window

Evidence, Adverse Effects & Future Directions

  • Key RCTs (depression): Holtzheimer 2017/SCC (42%/25% R/Rem at 30 mo); Ramasubbu 2020/SCC (50%/27% at 12 mo); Coenen 2019/slMFB (100%/50% — small pilot); Dougherty 2015/VC-VS (23%/20%); all small samples, most blinded phases non-significant
  • Psychiatric adverse effects (depression population): suicide attempt 3–16% (most likely reflects underlying illness severity, not device causation); depression 2–43%; hypomania/mania 1–23%; gait disturbance 5–36%; seizure 2–3%; cognitive effects common but often transient
  • Future directions: personalized preoperative biomarkers (facial expression, speech, wearables, fMRI); tractography-guided targeting; closed-loop DBS using local field potential beta-band recordings as sensing biomarkers to trigger stimulation only during symptomatic periods — representing a potential paradigm shift from continuous open-loop to adaptive, demand-driven stimulation
Source lectures
Surgical Treatments — Stephen Ferber, MD · Cleveland Clinic Foundation
Physical Principles of Neuromodulation/Brain Stimulation for Clinicians — Marom Bikson, PhD · City College of New York (CUNY)
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Clinical Pearls — DBS Overview

Source lectures
Surgical Treatments — Stephen Ferber, MD · Cleveland Clinic Foundation

Review Questions — DBS Overview

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Surgical Treatments — Stephen Ferber, MD · Cleveland Clinic Foundation
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Case Simulation — DBS Overview

Stepwise clinical vignettes. Explore all options freely before continuing.

DBS Subtopic · Circuit-Specific Targeting

Circuit-Specific DBS & Tractography

How psychiatric DBS evolved from landmark-based lead placement to patient-specific engagement of white matter pathways — across depression, OCD, and symptom-specific network targets — and what that changes for programming, troubleshooting, and patient selection.

Source lectures
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai
Circuit-specific DBS treats lead placement as a question of which white matter pathways are driven rather than where a contact sits in coordinate space. Targets derive from the parallel basal ganglia–thalamocortical loops (Parkinson disease: dorsolateral STN and GPi; OCD: ALIC and medial STN; depression: ventral capsule/ventral striatum, medial forebrain bundle, and subgenual cingulate), and the best-supported DBS and TMS sites share a functional-connectivity logic in which anti-correlated cortical sites respond to excitatory TMS and positively correlated sites to inhibitory TMS. SCC DBS was derived from imaging showing that area 25 down-regulation tracks recovery across treatments; landmark targeting helped about 60% of ECT-failure patients, but responders and non-responders were indistinguishable in standard space. Tractography seeded by each patient's modeled stimulation volume revealed a common responder map of four converging bundles (cingulum, frontostriatal fibers, forceps minor, uncinate fasciculus), and prospective tractography guidance raised response from about 41% to 73–90%, with a pooled retrospective analysis implicating missed left cingulum engagement in non-response. In OCD, responders were stimulated in ALIC white matter rather than the accumbens, and tractography-guided single-contact stimulation produced 85% response (24/28) with a compulsivity-specific effect and a lower limbic contact available for comorbid anhedonia. Once the lead is on target, programming reduces to current over time at fixed frequency (about 125–130 Hz) and pulse width, with evoked potentials and local field potentials aiding verification, and baseline connectivity profiles are emerging as retrospective candidates for patient selection and treatment biotyping.
Core themes

From Landmarks to Pathways: Depression Targeting

  • SCC DBS was designed to down-regulate a metabolically defined node, not to replace a lesion — area 25 decreased across successful treatments, and its effects are distributed across the brain
  • Landmark targeting helped about 60% of ECT-failure patients, but contact location in standard space did not separate responders from non-responders; non-responders lacked remote network changes
  • Modeled-stimulation tractography yields a common responder map of four bundles — cingulum, frontostriatal fibers, forceps minor, uncinate fasciculus — and individual contacts 1.5 mm apart can engage different tracts
  • Prospective tractography guidance raised response from about 41% to 73–90%; a pooled analysis (n=143) implicated missed left cingulum engagement, and the successor trial randomizes only after the target is confirmed
  • The same functional-connectivity logic links DBS and TMS sites, and the DLPFC TMS target should avoid the default-mode portion of DLPFC

OCD and Symptom-Specific Network Targeting

  • Accumbens-era OCD DBS gave about 52% response (n=70) over 10 to 600 days, with insomnia (46%) and hypomania (25%) and often two active contacts
  • Responders were stimulated in ALIC white matter, and the tract engaged (anterior thalamic radiation vs medial forebrain bundle) varies by patient despite identical structural lead positions
  • Tractography-guided ALIC DBS reached 85% response (24/28) with a single fixed contact; the common map includes prefrontal cortex, thalamus, STN, brainstem, and GPe
  • The target is specific for compulsivity, so non-responders likely need a different network, and a lower limbic contact can address comorbid depression or anhedonia
  • Symptom constructs map to networks — negative affect to SCC, compulsivity to ALIC, reward to medial forebrain bundle/ventral striatum — with preliminary extensions to schizophrenia and Parkinson apathy

Programming, Troubleshooting & Patient Selection

  • On target, stimulation is set near 130 Hz and 90 µs on one contact; current and time are the dose levers, up to a ceiling around 6 mA, guided by a local field potential readout
  • Frequency and pulse-width changes have not produced benefit in psychiatric targets; low-frequency stimulation is used mainly for gait and cognitive symptoms in Parkinson disease
  • Reproducible stimulation-evoked potentials verify target engagement and help estimate a starting dose; adjacent contacts may give different signals
  • Leads can be pulled up but not pushed deeper; off-trajectory or shallow leads require re-implantation, with position confirmed by intraoperative imaging
  • Retrospective baseline connectivity (SCC–mid-cingulate, ventral striatum–insula) may flag likely non-responders, and SCC connectivity predicts CBT versus medication response — emerging, not yet validated
Source lectures
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Clinical Pearls — Circuit-Specific DBS & Tractography

Source lectures
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Review Questions — Circuit-Specific DBS & Tractography

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Case Simulation — Circuit-Specific DBS & Tractography

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Modality · Convulsive Therapy

Electroconvulsive Therapy & Magnetic Seizure Therapy

Seizure-based treatments that remain among the most effective interventions in psychiatry — ECT induces generalized seizures using scalp electrodes; MST uses a magnetic coil to achieve focal seizures with markedly reduced cognitive side effects.

Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
ECT and Magnetic Seizure Therapy — Sarah Holly Hollingsworth Lisanby, MD · Arizona State University
Interventional Psychiatry Ethics: We Can, But Should We? — Jeffrey Zabinski, MD, MSW · Columbia University Irving Medical Center
ECT is the induction of a generalized tonic-clonic seizure under general anesthesia and muscle relaxation using alternating electrical current delivered through scalp electrodes. A typical acute course consists of 6–12 treatments administered three times per week. ECT has an exceptionally broad therapeutic spectrum — evidence supports efficacy in major depressive episodes, mania, catatonia, psychotic depression, schizophrenia, Parkinson's disease, epilepsy, NMS, and tardive dyskinesia. Its therapeutic index, however, is narrow: both efficacy and cognitive side effects are dose-related, making parameter optimization essential. The key dosing dimensions are electrode placement (bilateral temporal, right unilateral, bifrontal), pulse width (brief 1–2 ms vs. ultra-brief 0.25–0.3 ms), and seizure threshold titration. The current evidence-based optimum is 6× seizure threshold right unilateral ECT with ultra-brief pulse width — matching the efficacy of bilateral ECT with significantly reduced amnesia. MST was developed to further separate efficacy from cognitive side effects by inducing seizures with a magnetic coil, minimizing the intracranial electric field and sparing deep structures including the hippocampus. In the largest RCT to date (n=73), MST and RUL ultra-brief ECT showed comparable antidepressant remission rates (45% vs 42%) with significantly faster reorientation and significantly less anterograde and retrograde amnesia with MST.
Core themes

Dosing: Spatial & Temporal Parameters

  • Electrode placement controls the spatial distribution of the electric field in the brain — bilateral temporal (BT) spreads broadly; right unilateral (RUL) and bifrontal (BF) are more sparing of the left temporal lobe; all conventional placements stimulate the hippocampus above neural depolarization threshold
  • Pulse width is a key driver of cognitive side effects: ultra-brief (0.25–0.3 ms) reduces amnesia dramatically vs. brief pulse (1–2 ms) by inducing seizures at lower total charge and differentially activating axons vs. soma based on their different time constants
  • All electrical parameters matter independently — stimulation strength, electrode configuration, pulse characteristics, and train characteristics all have unique physiological contributions; you cannot substitute one for another
  • Current optimal balance: 6× seizure threshold RUL ECT + ultra-brief pulse — matches BL ECT efficacy (~71% responders, ~62% remitters) with significantly less amnesia (p<0.0001)
  • Anatomical variability means the same current delivers very different electric fields across patients — individualized amplitude titration (iLAST) and simulated E-field modeling may improve dosing precision

Mechanism: E-field vs. Seizure

  • Three competing models: (A) seizure drives efficacy, E-field drives side effects; (B) E-field drives efficacy, seizure drives side effects; (C) E-field × seizure interaction drives outcomes
  • MST tests Model A — by using magnetic stimulation to induce seizures with minimal intracranial E-field, it lowered cognitive side effects without sacrificing antidepressant efficacy, providing the strongest human evidence to date in support of Model A
  • TEST (Transcranial Electric Stimulation Therapy) tests Model B — delivers ECT-strength E-fields using bifrontal placement without inducing seizure; first double-blind RCT is underway
  • MIST (Multichannel Individualized Stimulation Therapy) enables Model C testing — 15 independent current sources allow multi-focal stimulation patterns tailored to target efficacy circuits while sparing memory circuits; integrated with EEG for seizure monitoring
  • ECT increases brain volume in a regionally specific manner and volume increases correlate with E-field strength — whether E-field alone causes this (or requires seizure) is the open question the TEST trial is designed to answer

MST Evidence & Future Directions

  • MST vs RUL ultra-brief ECT (JAMA Psychiatry 2023, n=73): 45% vs 42% remission — non-inferior efficacy with faster reorientation (p<0.01 at threshold, p<0.0001 at suprathreshold) and significantly less anterograde and retrograde amnesia (significant for ECT, not for MST)
  • CREST-MST trial (R01MH112815, NCT03191058) is a larger non-inferiority RCT vs ECT — results pending; FDA has provided guidance on what evidence would support MST device approval
  • Novel mechanism: cortical spreading depression (CSD) — a slowly propagating depolarization wave — occurs after ECT-induced seizures in both mouse models and human optical neuroimaging; its contribution to ECT efficacy or side effects is unexplored and may add a third mechanism beyond E-field and seizure
  • Understudied parameters include stimulus frequency (U-shaped seizure threshold curve suggests mid-range frequencies are most efficient), waveform shape (biphasic, multiphasic, pre-polarized), and current directionality (unidirectional trains more efficient than bidirectional in NHP studies)
Source lectures
ECT and Magnetic Seizure Therapy — Sarah Holly Hollingsworth Lisanby, MD · Arizona State University
Interventional Psychiatry Ethics: We Can, But Should We? — Jeffrey Zabinski, MD, MSW · Columbia University Irving Medical Center
Physical Principles of Neuromodulation/Brain Stimulation for Clinicians — Marom Bikson, PhD · City College of New York (CUNY)

Clinical Pearls — ECT / MST Overview

Source lectures
ECT and Magnetic Seizure Therapy — Sarah Holly Hollingsworth Lisanby, MD · Arizona State University

Review Questions — ECT / MST Overview

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
ECT and Magnetic Seizure Therapy — Sarah Holly Hollingsworth Lisanby, MD · Arizona State University

Case Simulation — ECT / MST Overview

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Modality · Rapid-Acting Pharmacotherapy

Ketamine & Esketamine

Glutamatergic agents that produce rapid, robust antidepressant effects — ketamine (racemic IV) and esketamine (intranasal Spravato) represent a mechanistic departure from monoaminergic antidepressants and the first new pharmacological approach to TRD in decades.

Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
Ketamine and Esketamine — Marcus Hughes, MD & Gerard Sanacora, MD PhD · Yale University
Interventional Psychiatry Ethics: We Can, But Should We? — Jeffrey Zabinski, MD, MSW · Columbia University Irving Medical Center
Ketamine is a racemic mixture (50/50 R- and S-enantiomers) originally developed as a dissociative anesthetic. Its antidepressant potential was identified through NMDA receptor antagonism research in the 1990s, with the first prospective RCT conducted at the West Haven VA by Yale faculty (Berman, Crystal, Heninger, Charney). Subsequent decades of trials confirmed rapid and robust attenuation of depressive symptoms and suicidal ideation. In 2019, esketamine (the S-enantiomer, branded Spravato) received FDA approval for treatment-resistant depression, followed by approval for MDD with acute suicidal ideation in 2020. IV racemic ketamine remains off-label for all psychiatric indications. A typical acute induction course for either agent is twice weekly for four weeks, though clinical protocols vary. Response rates are approximately 50% and remission rates approximately 30% across the literature, with durability typically low — most patients require maintenance treatment. The ELECT trial (n=365, the largest prospective ketamine study to date) found IV ketamine non-inferior to ultra-brief right unilateral ECT in an outpatient population. Esketamine has also demonstrated superiority over quetiapine augmentation (n=676) as a next-step treatment after SSRI/SNRI failure, and received recent FDA approval as a monotherapy for TRD — the first and only such approval.
Core themes

Mechanism & Pharmacology

  • Primary mechanism: NMDA receptor antagonism on GABAergic interneurons → disinhibition of glutamate transmission → AMPA receptor activation → BDNF/TrkB signaling → synaptic plasticity and antidepressant effect; ketamine reverses stress-induced dendritic atrophy in medial prefrontal cortical neurons in animal models
  • Mu-opioid receptor involvement is an active area of investigation — naltrexone appears to attenuate ketamine's effects in some studies, but the mechanism may involve a functioning endogenous opioid system (beta-endorphin/BDNF pathway) rather than direct ketamine-opioid binding
  • Subjective experience (awe, mystical-type states) may independently contribute to antidepressant response — dissociation scores (CADSS) do not predict response, but "awe" scores do predict larger MADRS reductions out to 30 days (Price et al.)
  • Bioavailability varies critically by route: IV = 100%, intranasal = 30–50%, oral = 10–20% — oral formulations require much higher doses to compensate for gut loss
  • Racemic ketamine touches many receptors beyond NMDA; the full antidepressant mechanism is a sum of multiple receptor interactions, not NMDA antagonism alone

Evidence, Efficacy & Durability

  • ELECT trial (n=365): IV ketamine non-inferior to ultra-brief RUL ECT in outpatient MDD — notable limitations include comparison to unilateral (not bilateral) ECT and high ECT withdrawal rate post-randomization suggesting expectancy effects; ketamine vs ECT pulled analyses favor ECT, but ELECT N exceeds all prior comparison studies combined
  • Esketamine vs quetiapine augmentation (n=676): esketamine significantly outperformed, with ~27% remission — consistent with the broader ~30% remission benchmark
  • Durability is a central clinical challenge: single infusion effect ~1 week, multi-infusion series ~1 month; active maintenance strategies (pharmacological, psychosocial, psychotherapeutic, combined TMS+ketamine) are routinely needed
  • Active placebo design matters: ketamine vs midazolam shows smaller between-group differences than ketamine vs saline — expectancy inflation from perceived drug effects is a major confounder in psychoactive drug trials
  • Fewer prior antidepressant failures predict greater ketamine response (consistent with STAR*D data on diminishing returns with each subsequent failure)

Safety, Regulation & Equity

  • Esketamine REMS (Spravato): mandatory in-clinic administration, patient/provider/pharmacy registration, monitoring form per session, adverse event reporting — REMS data from 58,000+ patients over 5 years shows sedation and dissociation in most patients, clinically significant BP elevation (>180 systolic) in ~12% of patients over a treatment lifetime, and serious adverse events (true clinical definition: death/hospitalization/life-threatening) in ~1 in 1,000 sessions; 109 deaths and 70 completed suicides identified via global medical safety surveillance — within expected range for TRD population
  • IV racemic ketamine has no regulatory mandate, no registry, no required monitoring — risk of cognitive toxicity with increasing dose/duration is real (largely nonhuman data), and routine cognitive monitoring is recommended but not required
  • At-home ketamine models, compounded ketamine nasal sprays, and direct-to-consumer clinics are a growing concern — FDA has explicitly warned compounded ketamine products are not FDA-approved and lack safety data; misuse seizures of ketamine are rising while esketamine misuse is flat (REMS effect)
  • Racial and ethnic disparities: clinical trials of racemic ketamine are overwhelmingly white; large claims data show white patients are offered ketamine at higher rates than Black, Hispanic, and Asian patients seen for depression — a structural equity gap
Source lectures
Ketamine and Esketamine — Marcus Hughes, MD & Gerard Sanacora, MD PhD · Yale University
Interventional Psychiatry Ethics: We Can, But Should We? — Jeffrey Zabinski, MD, MSW · Columbia University Irving Medical Center

Clinical Pearls — Ketamine Overview

Source lectures
Ketamine and Esketamine — Marcus Hughes, MD & Gerard Sanacora, MD PhD · Yale University

Review Questions — Ketamine Overview

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Ketamine and Esketamine — Marcus Hughes, MD & Gerard Sanacora, MD PhD · Yale University

Case Simulation — Ketamine Overview

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Cross-Modality · Clinical Reasoning
Clinical Decision Making in Interventional Psychiatry
A framework for choosing, sequencing, and personalizing interventional psychiatry treatments — integrating patient-specific clinical factors, psychosocial context, circuit-based thinking, and real-world logistics.
Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
Clinical Decision Making — Tracy Barbour, MD & Golkoo Hosseini, MD · Massachusetts General Hospital · University of Pennsylvania
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
Clinical decision making in interventional psychiatry is not choosing from a menu. It is a longitudinal, multi-dimensional detective process that integrates diagnosis, treatment history, symptom phenomenology, brain network formulation, psychosocial factors, and practical access considerations — all weighted differently for each patient. Population-level evidence tells you what works on average; the clinician's job is to find what works for the person in front of you.
Key themes

The IPS Intake: 12-Domain Assessment

  • Reassess symptoms & diagnosis — don't accept the referring label; probe for bipolarity, psychosis, ADHD, trauma, personality disorders
  • "I've tried everything" requires dose, duration, and symptom-specific failure data (response vs remission vs recovery)
  • Distinguish tachyphylaxis vs true resistance; state vs trait effects; include paraclinical data (labs, EEG, neuropsych, genetic testing)
  • Define success with the patient: symptom reduction vs functional restoration vs patient-defined goals — including what symptom to target first

Circuit-Based Symptom Targeting

  • Anhedonia = mesolimbic (VTA→NAc); apathy = frontostriatal; executive dysfunction = DLPFC/frontoparietal; anxiety-driven avoidance = amygdala/salience network
  • Passive SI maps to vmPFC/sgACC; OCD to cortico-striatal loops; emotional heaviness to DMN hyperactivity
  • ECT acts broadly across networks; TMS targets specific circuits; ketamine restores global synaptic connectivity; VNS/DBS are sustained carriers
  • Unexpected early side effects are diagnostic — re-examine formulation before abandoning a modality

5-Axis Modality Selection Framework

  • Acuity — emergent (catatonia, psychosis, severe SI) → ECT; subacute stable TRD → TMS/ketamine; chronic refractory → VNS/DBS
  • Evidence — most data is sham-controlled, not head-to-head; comparative estimates are directional, not definitive
  • Risk-benefit — cognitive risk: ECT > ketamine > TMS; procedural: ECT/VNS/DBS > ketamine > TMS
  • Patient factors — psychotic features favor ECT; cognitive concerns favor TMS; bipolar depression well-established for ECT
  • Pragmatics/AAA — Available · Accessible · Affordable; non-clinical factors determine real-world feasibility and efficacy
Source lectures
Clinical Decision Making — Tracy Barbour, MD & Golkoo Hosseini, MD · Massachusetts General Hospital · University of Pennsylvania
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Clinical Pearls — Clinical Decision Making

Showing 0 pearls
Source lectures
Clinical Decision Making — Tracy Barbour, MD & Golkoo Hosseini, MD · Massachusetts General Hospital · University of Pennsylvania
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Review Questions — Clinical Decision Making

Select an answer to reveal the explanation. Explore all choices freely.

Source lectures
Clinical Decision Making — Tracy Barbour, MD & Golkoo Hosseini, MD · Massachusetts General Hospital · University of Pennsylvania
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Case Simulation — Clinical Decision Making

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Modality · Emerging Neuromodulation

Home Use & Emerging Noninvasive Neuromodulation

A rapidly expanding landscape of prescription and consumer devices — spanning cranioelectrotherapy stimulation (CES), transcranial electrical stimulation (tES), external cranial nerve stimulators, and FDA-cleared digital therapeutics — that patients increasingly access outside the clinic, with or without clinician guidance.

Source lectures
Home Use Devices — Linda Carpenter, MD · Brown University
FDA Approval of Home-Use Occipital and Trigeminal Stimulation for Depression — Andrew Leuchter, MD · UCLA; Linda Carpenter, MD · Brown University; Owen Muir, MD · Radial/Neurolief
FDA Approval of Home Use tDCS Brain Stimulation for Depression — Daniel Mansson · Flow Neuroscience
The home-use neuromodulation landscape spans four categories: cranioelectrotherapy stimulation (CES) devices — most grandfathered under pre-1976 FDA rules, requiring only a prescription from any licensed provider, with indications for anxiety and insomnia (and a higher evidentiary bar for depression since a 2019 FDA reclassification); transcranial electrical stimulation (tES), including tDCS and tACS, which use electrode montages to sub-threshold modulate cortical excitability — with the Flow Neuroscience tDCS device (anode F3/cathode F4, 2 mA, 30 min/session) receiving FDA approval in December 2025 as both monotherapy and adjunctive therapy for moderate-to-severe non-treatment-resistant MDD (pivotal Empower trial: 58% vs. 30% MADRS remission at 10 weeks; NNT ~4; effect size ~0.4 consistent with a 2025 meta-analysis across 20 high-quality tDCS RCTs; class A evidence designation); external peripheral nerve stimulators targeting trigeminal, occipital, and vagal pathways — most notably Proliv Rx (eCOT-NS), FDA-approved via Breakthrough Device pathway (HDRS-17 active-sham delta 8.6 points, Cohen's d >0.7, 32% remission vs. sham); and FDA-cleared prescription digital therapeutics (Rejoyn for MDD, EndeavorRx for ADHD, Somryst/SleepioRx for insomnia, Nightware for PTSD, Freespira for panic/PTSD, Mama LiftPlus for postpartum depression) — all backed by RCT evidence but likely underutilized in psychiatric practice.
Core themes

Device Categories & Mechanisms

  • CES: surface electrodes (ear clips or scalp sponges), sub-milliamp currents at 0.5–100 Hz; most grandfathered pre-1976; vestibular nerve stimulation at the mastoid process (Modius) is one CES variant with sham-controlled trial data for stress and mood
  • tES (tDCS/tACS): sub-threshold electrical stimulation modulating neuronal firing propensity; anodal stimulation depolarizes membrane potential increasing cortical excitability; cathodal stimulation hyperpolarizes and inhibits; montage determines target — standard antidepressant protocol uses anode F3 (left DLPFC) / cathode F4 (right DLPFC); Flow Neuroscience tDCS received US FDA approval December 2025 for moderate-to-severe MDD (both monotherapy and adjunctive)
  • External peripheral nerve stimulation: trigeminal (V1 branch, forehead) and occipital stimulators access brainstem monoamine nuclei via the trigeminal cervical complex (parallel to VNS mechanism); auricular/cervical eVNS accesses CN X → NTS → locus coeruleus, dorsal raphe, limbic/prefrontal circuits; vagus nerve also modulates the inflammatory cytokine axis and gut-brain axis
  • Digital therapeutics: FDA-cleared software as medical device; CBT-based (insomnia, depression, PTSD, panic, ADHD, substance use, postpartum depression); prescription-required; chronically underutilized in psychiatric practice

Evidence Landscape & Key Trials

  • Proliv (eCOT-NS for MDD): FDA-approved via Breakthrough Device pathway; pivotal RCT n=124; HDRS-17 active-sham delta 8.6 points (p=0.029); Cohen's d >0.7; 32% remission vs. sham; adherence 96%; benefit continued accumulating through week 16 open-label extension
  • Fisher Wallace Oak (tACS, MDD): triple-blind RCT; 65% vs. 53% response at week 4 per-protocol (p=0.005); primary ITT endpoint (week 2 BDI) narrowly missed significance (p=0.056)
  • Flow tDCS Empower trial (FDA approval basis): multicenter, fully remote, placebo-controlled RCT; 10 weeks blinded + 10 weeks open-label; moderate-to-severe MDD (mean HAMD 19.3); non-TRD; MADRS 58% vs. 30% remission; HAMD 45% vs. 25%; NNT ~4; effect size ~0.4; monotherapy response 52.3%; adjunctive response higher in absolute terms but lower odds ratio; real-world sleep benefit: 63% of users with high insomnia normalize sleep scores at 10 weeks
  • Monarch TNS (pediatric ADHD): 8-week overnight RCT; Cohen's d=0.5; NNT=3; QEEG frontal biomarker changes correlated with clinical response; auricular eVNS: 5 RCTs show some efficacy for depression but methods too heterogeneous to meta-analyze

Regulatory Landscape, Safety & Clinical Positioning

  • FDA regulatory pathway is device-category and indication-specific: a 510k clearance for migraine does not permit a 510k for depression (different product codes); depression and psychiatric indications require more rigorous evidence than neurology indications even for the same device platform
  • CES/tES risks are low — primarily skin/scalp irritation under electrodes; burn risk if electrode impedance is high (poor contact, hair interference); syncope risk with high-amplitude eVNS; possible hypomania/mood destabilization in bipolar or psychosis-prone patients — especially with excessive or unsupervised use
  • Consumer self-directed use is already happening: patients build DIY tDCS rigs, purchase auricular eVNS devices directly, and access CES devices via downloaded prescription forms; psychiatrists should proactively ask, document, and counsel rather than discover use incidentally
  • Two FDA approvals for in-home neuromodulation in depression now exist: Proliv Rx (eCOT-NS, peripheral nerve stimulation, adjunctive, ≥1 prior antidepressant failure) and Flow Neuroscience tDCS (direct cortical stimulation, both monotherapy and adjunctive, non-TRD moderate-to-severe MDD); Flow US launch expected Q2 2025 at ~$500–800 per device, not yet covered by insurance
Source lectures
Home Use Devices — Linda Carpenter, MD · Brown University
FDA Approval of Home-Use Occipital and Trigeminal Stimulation for Depression — Andrew Leuchter, MD · UCLA; Linda Carpenter, MD · Brown University; Owen Muir, MD · Radial/Neurolief
FDA Approval of Home Use tDCS Brain Stimulation for Depression — Daniel Mansson · Flow Neuroscience

Clinical Pearls — Emerging Neuromodulation

Source lectures
Home Use Devices — Linda Carpenter, MD · Brown University
FDA Approval of Home-Use Occipital and Trigeminal Stimulation for Depression — Andrew Leuchter, MD · UCLA; Linda Carpenter, MD · Brown University; Owen Muir, MD · Radial/Neurolief
FDA Approval of Home Use tDCS Brain Stimulation for Depression — Daniel Mansson · Flow Neuroscience

Review Questions — Emerging Neuromodulation

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Home Use Devices — Linda Carpenter, MD · Brown University
FDA Approval of Home-Use Occipital and Trigeminal Stimulation for Depression — Andrew Leuchter, MD · UCLA; Linda Carpenter, MD · Brown University; Owen Muir, MD · Radial/Neurolief
FDA Approval of Home Use tDCS Brain Stimulation for Depression — Daniel Mansson · Flow Neuroscience

Case Simulation — Emerging Neuromodulation

Stepwise clinical vignettes. Explore all options freely before continuing.

Overview
Cross-Modality · Foundational Principles

Scientific Foundations of Interventional Psychiatry

The conceptual, neurophysiological, and historical underpinnings of interventional psychiatry — from circuitopathy models of mental illness through the applied biophysics of brain stimulation modalities and the emerging concept of the field itself.

Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
Towards Interventional Brain Medicine — Charlie Palmer, MD · University of Pennsylvania; Mark George, MD · MUSC; Roy Hamilton, MD · University of Pennsylvania
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
Interventional psychiatry is undergoing a paradigm shift: psychiatric disorders are increasingly understood as circuitopathies — disorders of dysfunctional neurocircuits — analogous to epilepsy or Parkinson’s disease rather than purely phenomenological categories. The conceptual engine of this shift is circuit-based formulation. DSM diagnoses are clinical syndromes, not diseases: nine criteria permit 227 combinations that meet criteria for depression, so two patients can share a diagnosis without sharing a symptom, and different underlying diseases coalesce into similar presentations, exactly as in left heart failure. Good history, examination, and syndromal formulation therefore remain the foundation of care, and circuit-based formulation adds a layer on top: identify which symptom dimensions drive this patient’s impairment, link each to the circuits that compute it, and build a circuit-level treatment plan — feasible today even without clinical biomarkers. Anchoring at the circuit level is justified pathophysiologically (behavior, cognition, and emotion are circuit computations that molecular and synaptic changes ultimately modulate) and therapeutically (devices act at exactly that level, with anatomical and physiological specificity). The same logic supports an experimental-medicine approach to treatment development — explain pathophysiology in anatomy, physiology, and behavior, identify a response biomarker, and find the protocol that engages it — in place of the serendipity that has characterized psychiatry, and it dissolves the boundary between neurology and psychiatry: once conditions are viewed at the circuit level, the same devices treat both. Brain stimulation is uniquely positioned as the bridge, being simultaneously personalized (dosed to individual brain physiology), targeted (engaging specific circuits rather than the whole body), and scalable (one TMS chair can treat 12+ patients per day; accelerated protocols compress week-long courses into days; in-home modalities are emerging). The field faces a genuine access crisis: psychiatric emergencies are at historical highs while wait times for specialist care run months; the “silver tsunami” of aging-related neurodegenerative disease will outpace the specialist workforce. Brain stimulation — and the integrated care models that deploy it across neurology and psychiatry together — represents the most viable path to closing this gap.
Core themes

Circuit-Based Formulation & the Circuitopathy Framework

  • Psychiatric and neurological disorders are circuit-level diseases — a DLPFC–sgACC circuit common to depression identified across lesion, TMS, and DBS datasets (Siddiqi et al., 2021); treatment efficacy correlates with degree of circuit modulation
  • DSM diagnoses are clinical syndromes — phenomenological clusters of signs and symptoms that gather multiple underlying diseases — not diseases; nine criteria yield 227 combinations meeting criteria for depression, so “what are the biological mechanisms of depression?” is the wrong question, just as it is for left heart failure
  • Circuit-based formulation builds on the standard workup rather than replacing it: history, examination, and syndromal formulation first, then identify the symptom dimensions driving this patient’s impairment, map each to its circuit hubs, and select a circuit-level treatment plan — possible even without validated biomarkers
  • The circuit level is the right anchor pathophysiologically (behavior, cognition, and emotion are computed in circuits; molecular and synaptic changes matter by modulating circuit dynamics) and therapeutically (drugs act at the molecular level, behavioral therapies at the functional level, devices at the circuit level); causality runs both bottom-up and top-down
  • Brain stimulation is personalized (dosed to individual physiology — motor threshold, anatomical targeting, network mapping), targeted (medications produce off-target effects at 20–30%, while stimulation engages the dysregulated circuit and even ECT and VNS are becoming more focal through MST and fascicle-selective taVNS), and scalable (accelerated protocols compress courses to days; in-home wearables are emerging)

Neurology–Psychiatry Split: History, Barriers & the Case for Reunification

  • The divide originated in methodology (neurologists had mechanistic brain access; psychiatry evolved introspective and psychodynamic models under Descartes and Freud) — not in biological difference between the conditions they treat; the brain does not respect specialty boundaries
  • Patients pay the price: neurological patients frequently have psychiatric comorbidities that go unrecognized (depression in 10–20% of neurology patients; ~5% likely have TRD); psychiatric patients with neurological illness are bounced between specialties for years
  • Modalities are heavily siloed: TMS has essentially no clinical neurological approvals despite evidence across stroke rehabilitation, epilepsy, and Parkinson’s; DBS for psychiatric indications exists at only a handful of centers; insurance structures reinforce the divide
  • Strategies for reunification: combined neurology–psychiatry training programs, required IPS rotations for residents, multidisciplinary brain health centers, mobile TMS units for rural access, and collaborative care models embedding IPS in neurology and oncology clinics
  • Once conditions are anchored at the circuit level, specialty boundaries lose meaning — the same devices already treat neurological and psychiatric indications (DBS for movement disorders and OCD; VNS for epilepsy, stroke rehabilitation, and depression; TMS for migraine, depression, and OCD) — and the shared biological, clinical, and technological framework across invasive, convulsive, noninvasive, and procedural-pharmacological treatments is part of what justifies interventional psychiatry as a subspecialty

Treatment Resistance, Access Crisis, Workforce & Precision Treatment Development

  • STAR*D sustained benefit: only 25.7% of MDD patients achieve sustained benefit at 12 months from step 1; drops to 13.7% at step 2, 4.9% at step 3, 3.8% at step 4 — the quantitative case for earlier IPS referral
  • Approximately 1 in 3 MDD patients meets TRD criteria; the US suicide rate is at its highest since the Great Depression; yet wait times for psychiatric specialty care run months, and access disparities by geography and payer status are severe
  • The “silver tsunami” will worsen both crises: aging-related dementias, Parkinson’s, stroke, and epilepsy will surge; these conditions carry high psychiatric comorbidity rates the specialist workforce cannot absorb under the current siloed model
  • The main barrier to IPS adoption is lack of training — not stigma (ranked 6th in US surveys); 1 in 400 eligible US patients is ever offered ECT; device manufacturer training is not a substitute for supervised clinical education
  • Treatment development has leaned on serendipity rather than experimental medicine — a mechanistic, biomarker-driven approach that explains pathophysiology in anatomy, physiology, and behavior, identifies a response biomarker tracking clinical change, and finds the protocol that engages it — and treatment selection remains trial and error from group-level evidence; ketamine, neurosteroids, and several TMS protocols are the exceptions
Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
Towards Interventional Brain Medicine — Charlie Palmer, MD · University of Pennsylvania; Mark George, MD · MUSC; Roy Hamilton, MD · University of Pennsylvania
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
Physical Principles of Neuromodulation/Brain Stimulation for Clinicians — Marom Bikson, PhD · City College of New York (CUNY)
DBS Part 1: The Evolution of Circuit-Specific DBS — Martijn Figee, MD, PhD · Mount Sinai; Helen Mayberg, MD · Mount Sinai

Clinical Pearls — Scientific Foundations

Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
Towards Interventional Brain Medicine — Charlie Palmer, MD · University of Pennsylvania; Mark George, MD · MUSC; Roy Hamilton, MD · University of Pennsylvania
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Review Questions — Scientific Foundations

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
What is Interventional Psychiatry? — Peter Giacobbe, MD · University of Toronto; Nicholas Trapp, MD · University of Iowa
Towards Interventional Brain Medicine — Charlie Palmer, MD · University of Pennsylvania; Mark George, MD · MUSC; Roy Hamilton, MD · University of Pennsylvania
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Case Simulation — Scientific Foundations

Stepwise clinical vignettes. Explore all options freely before continuing.

Scientific Foundations · Physical Principles

Physical Principles of Stimulation

A device-agnostic physical framework for brain stimulation — transducer, waveform, dose, and titration — explaining why every modality is individually dosed and why the same dose produces different outcomes in different patients.

Source lectures
Physical Principles of Neuromodulation/Brain Stimulation for Clinicians — Marom Bikson, PhD · City College of New York (CUNY)
All neuromodulation — DBS, VNS, spinal cord stimulation, TMS, transcranial electrical stimulation, ultrasound, and light-based devices — works by applying energy to the body, and every device shares one architecture: a generator that plays a waveform, a cable that carries it, and a transducer (electrode, coil, vibrating element, or light source) that is the only site where energy passes between device and patient. The transducer determines the form of energy and its position determines where that energy enters; the waveform — pulse intensity, pulse duration, and repetition frequency — determines how the tissue is driven. Waveform together with transducer type and placement constitutes dose, which is defined by what is delivered rather than by outcome, governs the physiological effect, and is the only thing that distinguishes one device or program from another inside the body. Dose alone does not determine outcome: individual anatomy changes how much energy reaches the target and the state of the network changes how that energy is used, so the same dose produces different results in different patients. Dose is therefore almost always titrated, and the titration instructions — what to adjust, against which endpoint, guided by which images — are part of the intervention and must be documented. Because symptoms change too slowly to titrate against, titration usually relies on a biomarker such as the motor-threshold finger twitch, which is useful but is neither a marker of the disease nor a direct readout of the treatment mechanism. The parameter space is multidimensional, non-monotonic, and not reducible to a single metric such as charge, which is both the central difficulty and the central opportunity of the field.
Core themes

One Architecture for All Modalities: Generator, Cable, Transducer

  • All neuromodulation applies energy through the same chain: a generator that plays a waveform, a cable that carries it, and a transducer where energy passes between device and patient
  • The transducer sets the form of energy — electrode (electrical current), coil (magnetic field), vibrating element (ultrasound), light source (light) — and its position, not the generator’s or cable’s, sets where energy enters
  • Electrical stimulation always requires two transducers, with current delivered and returned; in DBS, energizing different contacts shifts the stimulated region
  • TMS deposits a time-varying magnetic field that induces an electrical current in tissue, and neurons are understood to respond to that induced current
  • The generator may be a wheeled console or an implanted can; its size and location do not determine where stimulation occurs

Waveform, Dose, and the Parameter Space

  • The waveform is a pulse (intensity, duration) repeated at a frequency to form a pulse train; real waveforms add pulse reversal, bursting, on-time, and noise
  • Dose is the waveform plus the type and placement of the transducer, defined by what is delivered rather than by outcome; two devices delivering the same dose have identical effects in the body, so convenience features must be judged separately
  • Position controls where, waveform controls how, and intensity does both — higher intensity increases the effect but also enlarges the stimulated region
  • Dose must be fully reported for a trial or protocol to be reproducible
  • The parameter space has as many dimensions as there are controllable knobs; responses are non-monotonic, parameters interact, and collapsing them into a single metric such as charge has not worked

Why Dose Is Always Titrated: Anatomy, Physiology, and Endpoints

  • The same dose delivers different energy to different brains because of anatomy (skull thickness, scalp-to-brain distance; differences as large as tenfold), including with invasive devices, leaving some patients underdosed and others overdosed
  • Brain state shapes what stimulation does — stimulation modulates ongoing activity rather than creating new activity — so tasks, symptom provocation, and state-gated or closed-loop delivery function as dose instructions
  • The titration protocol is part of the intervention and must be documented, including imaging-based placement decisions; much of the innovation lives in dose instructions, often originating with clinicians
  • Symptoms change too slowly to titrate against, so titration uses biomarkers — but a titration biomarker is not necessarily a marker of the disease or the mechanism (the finger twitch; paresthesia in spinal cord stimulation)
  • Motor threshold blends anatomy and physiology and assumes transfer across sites and waveforms; anatomy-only model scaling has not replaced it
Source lectures
Physical Principles of Neuromodulation/Brain Stimulation for Clinicians — Marom Bikson, PhD · City College of New York (CUNY)

Clinical Pearls — Physical Principles of Stimulation

Source lectures
Physical Principles of Neuromodulation/Brain Stimulation for Clinicians — Marom Bikson, PhD · City College of New York (CUNY)

Review Questions — Physical Principles of Stimulation

Tap any answer to see its explanation. All choices are freely explorable.

Source lectures
Physical Principles of Neuromodulation/Brain Stimulation for Clinicians — Marom Bikson, PhD · City College of New York (CUNY)

Case Simulation — Physical Principles of Stimulation

Stepwise clinical vignettes. Explore all options freely before continuing.

Cross-Modality

Ethics & Justice in Interventional Psychiatry

Ethical frameworks, access inequities, consent challenges, workforce composition, and the tensions that distinguish interventional psychiatry from ordinary prescribing — examined across ECT, TMS, ketamine, VNS, DBS, and psychedelics.

Source Lectures
Interventional Psychiatry Ethics: We Can, But Should We? — Jeffrey Zabinski, MD, MSW · Columbia University Irving Medical Center
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital
Interventional psychiatry operates at the intersection of extraordinary clinical promise and distinctive ethical complexity. The field's treatments are more technical, more monitored, and more symbolically powerful than ordinary prescribing — which amplifies both the stakes of getting consent right and the consequences of getting access wrong. Six core tensions structure the ethical terrain: access versus rigor, hope versus hype, autonomy versus vulnerability, innovation versus evidence, specialization versus scope of practice, and commercialization versus justice. Across every modality, the treatments that most need to reach patients with the greatest illness burden most frequently end up reaching those with the fewest barriers — academic center proximity, insurance coverage, time, and resources. Understanding these structural forces, paired with a historically humble recognition of psychiatry's own procedural missteps, is foundational to practicing interventional psychiatry with integrity.
Key Themes

What Makes IPS Ethically Distinct

  • Procedural consent and monitoring demands exceed ordinary prescribing
  • Often deployed in refractory, disabling, or life-threatening illness — raising hope stakes
  • Resource intensity and scarcity amplify every ethical decision
  • Transference and countertransference dynamics are heightened in procedure-based care
  • Historical missteps (lobotomy, unmodified ECT) demand ongoing humility

Access, Equity & Workforce

  • Access is an ethical outcome — an unreachable treatment is not a success
  • ECT: 49% of providers at academic centers; only 1% of providers are Black or African American
  • Ketamine: >40% of clinics offer at-home treatment; <30% run by psychiatrists
  • DBS/VNS face opposite problem: evidence without meaningful geographic reach
  • Workforce composition must reflect patient population — data gaps for TMS and ketamine persist

Consent, Monitoring & Commercialization

  • Patient desperation can compromise genuine voluntariness — consent must account for this
  • ECT over-objection and psychedelic consent thresholds remain live ethical debates
  • Modality-limited clinics risk structural bias: what is best becomes what is available
  • Commercial motives can distort treatment selection toward profitable over optimal
  • Ethical excellence means pluralistic evaluation, medical responsibility, and justice orientation
Source Lectures
Interventional Psychiatry Ethics: We Can, But Should We? — Jeffrey Zabinski, MD, MSW · Columbia University Irving Medical Center
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Clinical Pearls — Ethics & Justice

Source Lectures
Interventional Psychiatry Ethics: We Can, But Should We? — Jeffrey Zabinski, MD, MSW · Columbia University Irving Medical Center
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Review Questions — Ethics & Justice

Select an answer to reveal the explanation. Explore all choices freely.

Source Lectures
Interventional Psychiatry Ethics: We Can, But Should We? — Jeffrey Zabinski, MD, MSW · Columbia University Irving Medical Center
Circuit Based Formulation — Joan Camprodon, MD, PhD, MPH · Massachusetts General Hospital

Case Simulation — Ethics & Justice

Stepwise clinical vignettes. Explore all options freely before continuing.

Question Bank
All questions across modalities and subtopics — filter to focus your review.
0
Questions
0
Modalities
0
Subtopics
Filter:
All
TMS Overview
TMS Accelerated & SAINT
TMS Circuit Targeting
Psychedelics
Special Populations
VNS
DBS
DBS Circuit-Specific Targeting
ECT / MST
Ketamine
Clinical Decision Making
Emerging Neuromodulation
Scientific Foundations
Physical Principles of Stimulation
Ethics & Justice
Foundational
Intermediate
Advanced
Case Library
All clinical cases — filter by modality, subtopic, or complexity.
0
Cases
0
Modalities
0
Complexity levels
Filter:
All
TMS Overview
TMS Accelerated & SAINT
TMS Circuit Targeting
Psychedelics
Special Populations
VNS
DBS
DBS Circuit-Specific Targeting
ECT / MST
Ketamine
Clinical Decision Making
Emerging Neuromodulation
Scientific Foundations
Physical Principles of Stimulation
Ethics & Justice
Foundational
Intermediate
Advanced